Loading
The TRAVERSE trial demonstrates that testosterone supplementation does not increase the risk of prostate cancer diagnosis in a low-risk population.
“The bottom line for the trial in a secondary analysis pre-specified was that there were no more prostate cancers diagnosed in men on T replacement versus on Placebo”
The Peter Attia Drive · Jul 2024 · 1 episode · 56K views on this topicExtracted by a model; may misattribute who said what.